Post by PharmaShots

16,912 followers

"š‚šØš¦š›š¢š§ššš­š¢šØš§ š­š”šžš«ššš©š¢šžš¬ ššš«šž š­š”šž šŸš®š­š®š«šž šØšŸ šØš§šœšØš„šØš š²." That isn't just one executive's opinion; it's a perspective increasingly shared by physicians, key opinion leaders, and pharma partners across the oncology landscape. In this conversation, Jared Kelly, CEO of Oncolytics Biotech Inc., discusses why the industry is moving beyond single-agent therapies and embracing combination approaches to achieve more durable patient outcomes. Key takeaways: āœ”ļø Combination therapies are reshaping the future of cancer treatment. āœ”ļø Durable disease control can be just as meaningful as traditional response rates. āœ”ļø The next wave of oncology innovation will focus on combining therapies to maximize patient benefit. šŸŽ„ Hear Jared Kelly share his perspective on the future of combination immunotherapy in our latest PharmaShots CXO Talks episode. Do you believe combination therapy will become the standard of care across more cancer types? šŸŽ§ Watch & Listen Now: ā–¶ļø YouTube: https://lnkd.in/gKXt5ESC šŸŽ™ļø Spotify: https://lnkd.in/gUmtCU3Q šŸ“° Substack: https://lnkd.in/gdcJuBi6 #Oncology #CombinationTherapy #CancerResearch #Immunotherapy #Biotech #Pharma #ClinicalTrials #Innovation #Healthcare #PharmaShots

Post content

Video Content